As of today (2024-06-06), Oxurion NV's share price is €0.0001.
Oxurion NV's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.01. Hence, Oxurion NV's Price-to-Free-Cash-Flow Ratio for today is N/A.
The historical rank and industry rank for Oxurion NV's Price-to-Free-Cash-Flow or its related term are showing as below:
During the past 13 years, Oxurion NV's highest Price-to-Free-Cash-Flow Ratio was 43.00. The lowest was 4.92. And the median was 11.78.
XBRU:OXUR's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 30.425 * Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 79.60% per year.
During the past 5 years, the average Free Cash Flow per Share Growth Rate was 55.40% per year.
During the past 13 years, Oxurion NV's highest 3-Year average Free Cash Flow per Share Growth Rate was 79.60% per year. The lowest was -43.00% per year. And the median was -5.85% per year.
Oxurion NV Price-to-Free-Cash-Flow Historical Data
The historical data trend for Oxurion NV's Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Oxurion NV's Price-to-Free-Cash-Flow
For the Biotechnology subindustry, Oxurion NV's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oxurion NV's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oxurion NV's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Oxurion NV's Price-to-Free-Cash-Flow falls into.
Oxurion NV Price-to-Free-Cash-Flow Calculation
Oxurion NV's Price-to-Free-Cash-Flow ratio for today is calculated as
Oxurion NV's Share Price of today is €0.0001.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Oxurion NV's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.01.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
Oxurion NV Price-to-Free-Cash-Flow Related Terms
Thank you for viewing the detailed overview of Oxurion NV's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Oxurion NV is a clinical stage biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME). The Group's research and development facilities are located in Belgium .The Company is engaged in the development of drugs to treat back-of-the-eye diseases, more specifically, ophthalmologic pharmaceuticals to treat vascular retinal disorders, specifically DME.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XBRU:OXUR has been successfully added to your 